These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 20196739)

  • 1. High-density lipoprotein quantity or quality for cardiovascular prevention?
    Calabresi L; Gomaraschi M; Franceschini G
    Curr Pharm Des; 2010 May; 16(13):1494-503. PubMed ID: 20196739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Laboratory assessment of HDL heterogeneity and function.
    Movva R; Rader DJ
    Clin Chem; 2008 May; 54(5):788-800. PubMed ID: 18375481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physiological role and clinical relevance of high-density lipoprotein subclasses.
    von Eckardstein A; Huang Y; Assmann G
    Curr Opin Lipidol; 1994 Dec; 5(6):404-16. PubMed ID: 7712045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic determinants of HDL metabolism.
    Ossoli A; Gomaraschi M; Franceschini G; Calabresi L
    Curr Med Chem; 2014; 21(25):2855-63. PubMed ID: 24606513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Laboratory assessment of HDL heterogeneity and function].
    Movva R; Rader DJ
    Ann Biol Clin (Paris); 2009; 67(1):7-21. PubMed ID: 19189882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-Density Lipoprotein Subclasses and Their Role in the Prevention and Treatment of Cardiovascular Disease: A Narrative Review.
    Chen Q; Abudukeremu A; Li K; Zheng M; Li H; Huang T; Huang C; Wen K; Wang Y; Zhang Y
    Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39063097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health benefits of high-density lipoproteins in preventing cardiovascular diseases.
    Berrougui H; Momo CN; Khalil A
    J Clin Lipidol; 2012; 6(6):524-33. PubMed ID: 23312048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin).
    Khera AV; Demler OV; Adelman SJ; Collins HL; Glynn RJ; Ridker PM; Rader DJ; Mora S
    Circulation; 2017 Jun; 135(25):2494-2504. PubMed ID: 28450350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current Therapies Focused on High-Density Lipoproteins Associated with Cardiovascular Disease.
    Estrada-Luna D; Ortiz-Rodriguez MA; Medina-Briseño L; Carreón-Torres E; Izquierdo-Vega JA; Sharma A; Cancino-Díaz JC; Pérez-Méndez O; Belefant-Miller H; Betanzos-Cabrera G
    Molecules; 2018 Oct; 23(11):. PubMed ID: 30360466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should we routinely measure low-density and high-density lipoprotein subclasses?
    Rizzo M; Berneis K; Zeljkovic A; Vekic J
    Clin Lab; 2009; 55(11-12):421-9. PubMed ID: 20225664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distribution of low-density lipoprotein and high-density lipoprotein subclasses in patients with sarcoidosis.
    Vekic J; Zeljkovic A; Jelic-Ivanovic Z; Spasojevic-Kalimanovska V; Spasic S; Videnovic-Ivanov J; Ivanisevic J; Vucinic-Mihailovic V; Gojkovic T
    Arch Pathol Lab Med; 2013 Dec; 137(12):1780-7. PubMed ID: 24283859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-density lipoprotein subclasses and apolipoprotein A-I.
    Duriez P; Fruchart JC
    Clin Chim Acta; 1999 Aug; 286(1-2):97-114. PubMed ID: 10511287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between plasma phospholipid transfer protein activity and HDL subclasses among patients with low HDL and cardiovascular disease.
    Cheung MC; Wolfbauer G; Brown BG; Albers JJ
    Atherosclerosis; 1999 Jan; 142(1):201-5. PubMed ID: 9920522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The biological activity of high-density lipoprotein fractions and their role in the development of cardiovascular diseases].
    Babintseva YD; Camont L; Chapman J; Lhomme M; Karagodin VP; Kontush A; Orekhov AN
    Ter Arkh; 2016; 88(9):111-118. PubMed ID: 28635814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of established hypolipidemic drugs on HDL concentration, subclass distribution, and function.
    Gomaraschi M; Adorni MP; Banach M; Bernini F; Franceschini G; Calabresi L
    Handb Exp Pharmacol; 2015; 224():593-615. PubMed ID: 25523003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between plasma lipid concentrations and HDL subclasses.
    Yang Y; Yan B; Fu M; Xu Y; Tian Y
    Clin Chim Acta; 2005 Apr; 354(1-2):49-58. PubMed ID: 15748599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacologic elevation of high-density lipoproteins: recent insights on mechanism of action and atherosclerosis protection.
    Meyers CD; Kashyap ML
    Curr Opin Cardiol; 2004 Jul; 19(4):366-73. PubMed ID: 15218398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-density lipoprotein functionality in coronary artery disease.
    Kosmas CE; Christodoulidis G; Cheng JW; Vittorio TJ; Lerakis S
    Am J Med Sci; 2014 Jun; 347(6):504-8. PubMed ID: 24603157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preferential distribution of amphotericin B lipid complex into human HDL3 is a consequence of high density lipoprotein coat lipid content.
    Kennedy AL; Wasan KM
    J Pharm Sci; 1999 Nov; 88(11):1149-55. PubMed ID: 10564063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.